Records containing: Lateral Canthal Lines

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2024-12-10
  A Prospective Open-label, Multicenter Study Evaluating Princess® RICH in Correction of Fine Lines
• CLINICAL_TRIALS study record update · 2024-08-09
  A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2023-10-05
  A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2023-07-17
  A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
• CLINICAL_TRIALS study record update · 2023-06-27
  A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2023-06-18
  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2023-06-18
  A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2023-04-21
  A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2022-07-26
  Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2022-02-18
  Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2021-09-10
  Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2021-03-19
  Phase II, Randomized, Double-blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2020-08-28
  A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines In Adults
• CLINICAL_TRIALS study record update · 2020-08-28
  A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
• CLINICAL_TRIALS study record update · 2019-11-22
  A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)
• CLINICAL_TRIALS study record update · 2019-07-05
  ClinicalTrials.gov study NCT02248844
• CLINICAL_TRIALS study record update · 2016-03-14
  ClinicalTrials.gov study NCT02195687
• CLINICAL_TRIALS study record update · 2014-05-29
  Dose Finding Study of Botulinum Neurotoxin Type A In Subjects With Crow's Feet (Lateral Canthal Lines)
• CLINICAL_TRIALS study record update · 2014-01-30
  A Phase 2, Double-Blind, Randomized, 4-Arm, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
• CLINICAL_TRIALS study record update · 2014-01-17
  A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
• CLINICAL_TRIALS study record update · 2014-01-17
  A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment Lateral Canthal Lines in Adults
• CLINICAL_TRIALS study record update · 2014-01-10
  Clinical Trial to Evaluate ANT-1401 in Subjects With Lateral Canthal Lines
• CLINICAL_TRIALS study record update · 2013-11-19
  A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, to Treat Moderate to Severe Lateral Canthal Lines in Adults.
• CLINICAL_TRIALS study record update · 2013-11-19
  A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Administration of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
• CLINICAL_TRIALS study record update · 2013-11-19
  A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults